Christine E Swenson

US Patent:

6352716, Mar 5, 2002

Filed:

Aug 18, 1993

Appl. No.:

08/108822

Inventors:

Andrew S. Janoff - Yardley PA
Mircea C. Popescu - Plainsboro NJ
Alan L. Weiner - Lawrenceville NJ
Lois E. Bolcsak - Lawrenceville NJ
Paul A. Tremblay - Hamilton NJ
Christine E. Swenson - Princeton Junction NJ

Assignee:

The Liposome Company Inc. - Princeton NJ

International Classification:

A61K 9127

US Classification:

424450, 264 41, 264 46, 424 121, 424 91, 436829, 514 78, 514182, 514887, 514967

Abstract:

Methods and compositions are described for the preparation of bioactive agents entrapped in lipid vesicles the bilayers of which comprise a salt form of an organic acid derivative of a sterol, such as the tris-salt form of a sterol hemisuccinate, and to bompositions comprising a mixtue of tris(hydroxymethyl)aminomethane salt of cholesteryl hemisuccinate with either an antifungal compound or a peptide. These compositions have various applications in vivo.

US Patent:

7842676, Nov 30, 2010

Filed:

Oct 25, 2006

Appl. No.:

11/586215

Inventors:

Andrew Janoff - Yardley PA, US
Lawrence Mayer - North Vancouver, CA
John Redman - Mullica Hills NJ, US
Christine Swenson - Princeton Jct NJ, US

Assignee:

Celator Pharmaceuticals, Inc. - Princeton NJ

International Classification:

A01N 43/04
A61K 31/70

US Classification:

514 50

Abstract:

Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of irinotecan and floxuridine. Such methods are particularly useful in the treatment of cancer patients with advanced solid tumors.

US Patent:

8092828, Jan 10, 2012

Filed:

Feb 15, 2008

Appl. No.:

12/032583

Inventors:

Arthur Louie - Princeton NJ, US
Christine Swenson - Princeton Jct NJ, US
Lawrence Mayer - North Vancouver, CA
Andrew Janoff - Yardley PA, US

Assignee:

Celator Pharmaceuticals, Inc. - Princeton NJ

International Classification:

A61K 9/127
A61K 31/00

US Classification:

424450, 514 1

Abstract:

Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders.

US Patent:

20100189771, Jul 29, 2010

Filed:

Oct 25, 2006

Appl. No.:

12/091738

Inventors:

Lawrence Mayer - North Vancouver, CA
Christine Swenson - Princeton Jct NJ, US
Andrew Janoff - Yardley PA, US
John Redman - Mullica Hills NJ, US

International Classification:

A61K 31/7068
A61P 35/00
A61K 9/127

US Classification:

424450, 514 50

Abstract:

Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of irinotecan and floxuridine. Such methods are particularly useful in the treatment of cancer patients with advanced solid tumors.

US Patent:

20100303895, Dec 2, 2010

Filed:

Feb 15, 2008

Appl. No.:

12/526930

Inventors:

Arthur Louie - Princeton NJ, US
Christine Swenson - Princeton Jct NJ, US
Lawrence Mayer - North Vancouver, CA
Andrew Janoff - Yardley PA, US

International Classification:

A61K 31/704
A61K 9/127
G01N 33/50
A61P 35/02

US Classification:

424450, 514 34, 436 94

Abstract:

Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders.

US Patent:

60868511, Jul 11, 2000

Filed:

Jun 24, 1997

Appl. No.:

8/881651

Inventors:

Lawrence T. Boni - Monmouth Junction NJ
Andrew S. Janoff - Yardley PA
Sharma R. Minchey - Monmouth Junction NJ
Walter R. Perkins - Monmouth Junction NJ
Christine E. Swenson - Princeton Junction NJ
Patrick L. Ahl - Princeton NJ
Thomas S. Davis - Valhalla NY

Assignee:

The Liposome Company, Inc. - Princeton NJ

International Classification:

A61K 4904
A61K 9127
B01J 1302
B32B 516

US Classification:

424 94

Abstract:

This invention provides a composition containing a sized liposome comprising a lipid and an inducer; the sized liposome has a diameter of at most about 1 micron and the inducer is present in an amount effective to induce interdigitation-fusion of the sized liposome. Also provided herein are interdigitation-fusion liposomes and gels, and methods of making the same.

US Patent:

49816926, Jan 1, 1991

Filed:

Aug 18, 1987

Appl. No.:

7/086467

Inventors:

Mircea Popescu - Plainsboro NJ
Christine E. Swenson - Plainsboro NJ
Sterling C. Johnson - Skillman NJ
Robert P. Lenk - Lambertville NJ

Assignee:

The Liposome Company, Inc. - Princeton NJ

International Classification:

A61K 9127
A61K 3722
A61K 4505

US Classification:

424422

Abstract:

A method of treating, by intramammary infusion of liposomes, Brucella spp. infections in an animal by administration of a therapeutically effective amount of aminoglycoside in liposome form, also being a method of administering a therapeutic agent in liposome form to a proximal mammary lymph node or mammary tissue of an animal.

US Patent:

54158672, May 16, 1995

Filed:

Aug 11, 1993

Appl. No.:

8/105764

Inventors:

Sharma R. Minchey - Monmouth Junction NJ
Christine E. Swenson - Princeton Junction NJ
Andrew S. Janoff - Yardley PA
Lawrence Boni - Monmouth Junction NJ
Kathy A. Stewart - Morrison IL
Walter Perkins - Plainsboro NJ

Assignee:

The Liposome Company, Inc. - Princeton NJ

International Classification:

A61K 9127

US Classification:

424450

Abstract:

High ratio active agent:lipid complexes, their preparation and use are disclosed. Particular reference is made to cephalosporin:lipid complex and iodinated contrast agent:lipid complex. Use of high ratio cephalosporin:lipid complex in bacterial prophylaxis, and particularly bacteremia prophylaxis, including a method of preventing bacterial infection in an animal over an extended period comprising the step of administering to said animal a high ratio cephalosporin:lipid complex is further disclosed as is the use of high ratio iodinated contrast agent:lipid complex in X-ray applications.